Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported Q2 CY2025 results exceeding the market’s revenue ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

Full-year 2025 revenue and adjusted EBITDA guidance were raised, reflecting strong commercial execution and new product launches. These 10 stocks could mint the next wave of millionaires › Exact ...

Exact Sciences stock crashed Wednesday after the company inked a deal for the exclusive eights to Freenome's blood-based ...

Exact Sciences Corp. a annoncé l'extension de son partenariat avec Humana Inc. afin d'améliorer l'accès au dépistage du ...

Cologuard Plus, lancé en mars 2025, a reçu l’approbation de la FDA, la couverture Medicare et l’inclusion dans les directives du Groupe de travail américain sur les services préventifs. Le test est ...

On Tuesday, Stifel reaffirmed its Buy rating and $67.00 price target for Exact Sciences (NASDAQ: EXAS), following the announcement of a Medicare reimbursement increase for the company's Cologuard ...

Exact Sciences et Humana élargissent leur partenariat pour le dépistage du cancer colorectal avec le test Cologuard Plus 31/07 CI Exact Sciences Corporation Presents at 45th Annual William Blair ...

In a detailed assessment, Stifel outlined a scenario where Cologuard Plus could launch on April 1, 2025, with Medicare Part B immediately reimbursing the CDLT rate and Medicare Part C following suit ...

Exact Sciences EXAS released strong test results for its next-generation Cologuard test that pushed shares up 9% in after-hours trading. The strength of these results has made investors hopeful ...

Exact Sciences delivered strong first-quarter results on better-than-anticipated Cologuard expansion that allowed management to increase its 2023 sales outlook and accelerate its timeline to ...